$2.09
-0.21-8.93%
At close: -
$2.10
0.010.48%
After Hours: 7:26 PM EDT
Comments
Loading...
Latest news for Outlook Therapeutics (NASDAQ:OTLK) Stock
Outlook Therapeutics Stock (NASDAQ: OTLK)
Categories: All
Friday, January 17, 2025
Thursday, January 16, 2025
Monday, January 06, 2025
Friday, December 27, 2024
Friday, December 13, 2024
Wednesday, December 04, 2024
Tuesday, December 03, 2024
Monday, December 02, 2024
Friday, November 29, 2024
Wednesday, November 27, 2024
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Nasdaq Down Over 100 Points; HP Shares Plunge
- Dow Falls Over 100 Points; US Crude Oil Stocks Decline
- US Stocks Mixed; Economy Grows By 2.8% In Q3
- Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
- Outlook Therapeutics shares are trading lower...
- Outlook Therapeutics Announces Preliminary To...
Friday, October 18, 2024
Thursday, October 03, 2024
Wednesday, September 04, 2024
Tuesday, September 03, 2024
Thursday, August 15, 2024
Wednesday, August 14, 2024
Monday, July 08, 2024
Tuesday, May 28, 2024
Friday, May 17, 2024
Wednesday, May 15, 2024
Monday, May 13, 2024
Thursday, May 02, 2024
Friday, April 12, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
Monday, March 25, 2024
Friday, March 22, 2024
- Gold Moves Lower; Lululemon Shares Plummet
- Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Dow Dips 200 Points; Nike Shares Fall After Q3 Results
- Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?
- Outlook Therapeutics shares are trading highe...
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Market-Moving News for March 22nd
- On 21 March 2024, EU's CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Outlook Therapeutics' Lytenava, Intended For Treatment Of Neovascular Age-related Macular Degeneration